Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New developments in osteoporosis

M R McClung1

  • 1Oregon Osteoporosis Center, Providence Health System, Portland 97213-2967, USA.

Comprehensive Therapy
|December 24, 1997
PubMed
Summary
This summary is machine-generated.

New osteoporosis treatments offer hope and are now integral to clinical management. This review explores recent advancements in osteoporosis therapy and their practical applications.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment rates and healthcare costs of patients with fragility fracture by site of care: a real-world data analysis.

Archives of osteoporosis·2023
Same author

Osteoanabolic therapy for osteoporosis in women.

Climacteric : the journal of the International Menopause Society·2021
Same author

A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2020
Same author

Effect of denosumab on trabecular bone score in postmenopausal women with osteoporosis.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2017
Same author

Observations following discontinuation of long-term denosumab therapy.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2017
Same author

Cancel the denosumab holiday.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2016
Same journal

Heparin-induced thrombocytopenia and thrombosis.

Comprehensive therapy·2011
Same journal

Antiplatelet therapy in cardiovascular disease.

Comprehensive therapy·2011
Same journal

Genetics of cardiovascular disease.

Comprehensive therapy·2011
Same journal

Septic renal vein thrombosis complicated by septic pulmonary embolism.

Comprehensive therapy·2011
Same journal

Gout and hyperuricemia.

Comprehensive therapy·2011
Same journal

Problems with computerized health records.

Comprehensive therapy·2011
See all related articles

Area of Science:

  • Bone Metabolism and Endocrinology
  • Geriatric Medicine
  • Pharmacology

Background:

  • Osteoporosis is a significant public health concern, characterized by low bone mass and microarchitectural deterioration.
  • Historically, treatment options were limited, leading to high fracture rates and reduced quality of life.
  • Recent scientific breakthroughs have transformed the landscape of osteoporosis management.

Purpose of the Study:

  • To review recent advancements in the pharmacological and non-pharmacological treatment of osteoporosis.
  • To contextualize these new developments within current clinical practice.
  • To provide clinicians with an updated perspective on managing osteoporosis effectively.

Main Methods:

  • Literature review of recent clinical trials and therapeutic guidelines.

Related Experiment Videos

  • Synthesis of evidence on novel osteoporosis medications and treatment strategies.
  • Analysis of the practical integration of new therapies into patient care.

    • Main Results:

    • Several new therapeutic agents have demonstrated efficacy in increasing bone mineral density and reducing fracture risk.
    • Emerging treatments target specific pathways involved in bone remodeling and resorption.
    • The clinical application of these advancements is expanding, offering improved outcomes for patients.

    Conclusions:

    • Osteoporosis is now a manageable condition with effective therapeutic options available.
    • New developments in osteoporosis treatment are crucial for improving patient outcomes and reducing the burden of fractures.
    • Clinicians should stay abreast of these advancements for optimal patient care.